177 related articles for article (PubMed ID: 18976802)
1. Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma.
Adley BP; Gleason KJ; Yang XJ; Stack MS
Gynecol Oncol; 2009 Feb; 112(2):319-24. PubMed ID: 18976802
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
3. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
[TBL] [Abstract][Full Text] [Related]
4. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
6. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells.
Fishman DA; Bafetti LM; Stack MS
Invasion Metastasis; 1996; 16(3):150-9. PubMed ID: 9186550
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary.
Okamoto T; Niu R; Yamada S
Mol Hum Reprod; 2003 Oct; 9(10):569-75. PubMed ID: 12970394
[TBL] [Abstract][Full Text] [Related]
9. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis.
Cai KQ; Yang WL; Capo-Chichi CD; Vanderveer L; Wu H; Godwin AK; Xu XX
Mol Carcinog; 2007 Feb; 46(2):130-43. PubMed ID: 17131304
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
[TBL] [Abstract][Full Text] [Related]
11. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
Kamat AA; Fletcher M; Gruman LM; Mueller P; Lopez A; Landen CN; Han L; Gershenson DM; Sood AK
Clin Cancer Res; 2006 Mar; 12(6):1707-14. PubMed ID: 16551853
[TBL] [Abstract][Full Text] [Related]
12. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
13. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
15. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
16. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression.
Barbolina MV; Adley BP; Ariztia EV; Liu Y; Stack MS
J Biol Chem; 2007 Feb; 282(7):4924-4931. PubMed ID: 17158885
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
Cheung LW; Leung PC; Wong AS
Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.
Fishman DA; Liu Y; Ellerbroek SM; Stack MS
Cancer Res; 2001 Apr; 61(7):3194-9. PubMed ID: 11306508
[TBL] [Abstract][Full Text] [Related]
19. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2.
Young TN; Rodriguez GC; Rinehart AR; Bast RC; Pizzo SV; Stack MS
Gynecol Oncol; 1996 Jul; 62(1):89-99. PubMed ID: 8690299
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
